Will the U.S. Food and Drug Administration approve the supplemental New Drug Application for mitapivat by November 1, 2026?
How this resolves
Resolves YES if the U.S. Food and Drug Administration issues an official approval letter or announcement for the supplemental New Drug Application (sNDA) for mitapivat on or before November 1, 2026. Resolves NO if the agency issues a Complete Response Letter or reaches no approval determination by that date.
The crowd consensus and the AI's estimate stay hidden until you make your own call — no anchoring, no herding.
Make your call first — no peeking at the crowd or the AI.
The Presage is a daily forecasting platform: call real-world events before anyone reveals their hand, then build a verified track record of your judgment over time. See how it works.
Not investment advice · Research & educational use only · No money — points only. Terms · Privacy